This finding, if confirmed in the future, means that the presence of tumor-associated tissue eosinophilic infiltration can predict negativity for HER2-NEU, minimizing the subsequent use of immunohistochemistry and allowing for more cost-effective rapid initiation of the treatment protocol in certain situations and resource-limited settings. This evidence concerns the gene ERBB2 and neoplasm.